Advertisement
Review ArticleReview Article

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

Rina Aharoni, Ron Milo and Ruth Arnon
Francesca Levi-Schaffer, Associate Editor
Pharmacological Reviews November 2024, 76 (6) 1133-1158; DOI: https://doi.org/10.1124/pharmrev.124.000927

Article Information

vol. 76 no. 6 1133-1158
DOI 
https://doi.org/10.1124/pharmrev.124.000927
PubMed 
39406508
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0031-6997
Online ISSN 
1521-0081
History 
  • Received January 31, 2024
  • Revision received August 14, 2024
  • Accepted August 20, 2024
  • Published online October 16, 2024.

Article Versions

Copyright & Usage 
Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Rina Aharoni,
  2. Ron Milo, and
  3. Ruth Arnon
  1. Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel (Ri.A., Ru.A.); and Department of Neurology, Barzilai Medical Center, Ashkelon, Israel, and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel (R.M.)
  1. Francesca Levi-Schaffer, Associate Editor
  1. Address correspondence to:
    Dr. Ruth Arnon, Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel, 761001. E-mail: ruth.arnon{at}weizmann.ac.il
View Full Text

Statistics from Altmetric.com

Article usage

Article usage:

No statistics are available.

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Review ArticleReview Article

Glatiramer Acetate for the Treatment of Multiple Sclerosis

Rina Aharoni, Ron Milo and Ruth Arnon
Pharmacological Reviews November 1, 2024, 76 (6) 1133-1158; DOI: https://doi.org/10.1124/pharmrev.124.000927
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement